NPPA and myeloid sarcoma: We first examine laquinimod, a drug developed specifically for MS that has KP-modulating properties, and then review other repurposed drugs (such as alpha-lipoic acid and metformin) that are being investigated for their ability to influence KP and mitochondrial dysfunction in MS.